N163-166 (MOD6)

N163-166 (MOD6) is an investigational small peptide belonging to a novel class of orally active testosterone-inducing compounds derived from the voltage-dependent anion channel 1 (VDAC1). Chemically it is built from a short stretch of the VDAC1 protein sequence, with the tetrapeptide RVTQ identified as the biologically active core; the MOD6 designation refers to structural modifications intended to slow enzymatic degradation so the peptide remains active after oral administration ^[1]. Rather than delivering an external androgen, it is designed to enhance the body's endogenous synthesis of testosterone.

The concept grew out of research into how cholesterol, the precursor of all steroid hormones, is imported into the mitochondria of steroid-producing cells, the rate-limiting step of steroidogenesis. VDAC1 sits in a multiprotein complex that manages this import, and the adaptor protein 14-3-3 epsilon acts as a brake on the process. Investigators first showed that an intratesticular 25 amino acid fusion peptide spanning VDAC1 residues 159 to 172 blocked the VDAC1 and 14-3-3 epsilon interaction and raised circulating androgens; they then distilled that peptide down to its active core and developed synthetic derivatives suitable for oral dosing ^[1].

In published animal work, oral administration of these VDAC1-derived peptides increased circulating testosterone in male rats in a specific manner, acting within the hypothalamic-pituitary-gonadal axis; several synthetic derivatives robustly raised androgen levels, and a lead compound was profiled across the lifespan of aging rats ^[1]. The authors framed the approach as a self-regulating strategy that works through natural feedback rather than flooding the system with exogenous hormone.

N163-166 (MOD6) is not an approved medication and is offered strictly as a research chemical. The supporting evidence is preclinical and traces to a focused research program, so it sits at an early, frontier stage of development for endogenous testosterone support.

This is a preclinical research peptide with no human safety data at all; everything known comes from rats. In theory, pushing endogenous testosterone up could carry the usual concerns of raising androgens, including effects on red blood cell count, prostate tissue, mood, and the natural feedback that governs sperm production, but none of that has been mapped for this compound in people. Purity and identity of any material sold under this code are unverified. Treat it as experimental, handle it as a lab reagent, and understand there is no established therapeutic window in humans.

N163-166 (MOD6) emerged from the laboratory of Vassilios Papadopoulos and colleagues at the Research Institute of the McGill University Health Centre, working with collaborators at the University of Southern California, as part of a program to raise testosterone by targeting the very first, rate-limiting step of steroid synthesis. The group had previously shown that an intratesticular fusion peptide spanning amino acids 159 to 172 of the mitochondrial channel VDAC1 could increase circulating testosterone by disrupting the inhibitory grip of the adaptor protein 14-3-3 epsilon on cholesterol import.

In work published in Frontiers in Endocrinology in 2022 and 2023, they distilled that activity down to a four-amino-acid active core, RVTQ, and used it as a platform to engineer synthetic derivatives that could survive oral dosing. Screening in male rats identified eleven active compounds and, from these, four that robustly and specifically raised androgen levels, with a lead derivative profiled across the lifespan of aging Brown-Norway rats. The MOD6 designation reflects stabilizing modifications intended to protect the small peptide from rapid breakdown; the compound remains an investigational research agent, with its effects to date established only in animals.

N163-166 (MOD6) has generated genuine excitement for the elegance of its approach; instead of replacing testosterone from outside, it aims to release the body's own production brake so the testes make more hormone through the natural gonadal axis. This source-level strategy is appealing because, in the rat studies that introduced it, the effect was specific to androgens and did not spill over into adrenal corticosterone, and the researchers noted that the mechanism appears self-limiting in a way that could reduce abuse potential.

For those interested in age-related decline in gonadal function, the idea of gently restoring youthful output at its origin is compelling. Honesty requires emphasizing that this promise is, so far, entirely preclinical; the supporting evidence comes from male rats, the human dose-response and safety are unknown, and subjective effects in people have not been established. It is fairest to present it as a scientifically intriguing investigational peptide rather than a proven therapy.